Foundry Healthcare IntMom Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 12.15% |
2TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 11.45% |
3ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 7.62% |
4GH | GUARDANT HEALTH INC | Healthcare | $20.67B | 6.35% |
5MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 3.92% |
6ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 3.21% |
7APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 3.10% |
8PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $8.77B | 2.69% |
9SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 2.67% |
10PACS | PACS GROUP INC | Healthcare | $7.30B | 2.24% |
11COGT | COGENT BIOSCIENCES INC | Healthcare | $6.68B | 2.05% |
12ERAS | ERASCA INC | Healthcare | $5.96B | 1.83% |
13DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 1.77% |
14ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 1.72% |
15TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 1.62% |
16CELC | CELCUITY INC | Healthcare | $4.31B | 1.32% |
17DYN | DYNE THERAPEUTICS INC | Healthcare | $3.92B | 1.21% |
18RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 1.17% |
19ALMS | ALUMIS INC | Healthcare | $3.65B | 1.12% |
20ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 1.09% |
21GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 1.06% |
22RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 1.06% |
23GRAL | GRAIL INC | Healthcare | $3.12B | 0.96% |
24MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.92% |
25VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.85% |
26KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.82% |
27TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.79% |
28IMNM | IMMUNOME INC | Healthcare | $2.53B | 0.78% |
29SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.75% |
30NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.71% |
31PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 0.69% |
32MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $2.23B | 0.69% |
33SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.69% |
34AXGN | AXOGEN INC | Healthcare | $2.12B | 0.65% |
35AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.65% |
36GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.64% |
37RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.63% |
38NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.62% |
39SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.62% |
40DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 0.59% |
41TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.59% |
42NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.58% |
43ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.86B | 0.57% |
44STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.56% |
45ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.54% |
46BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.53% |
47TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.53% |
48ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.52% |
49FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.52% |
50MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.56B | 0.48% |
51SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.46% |
52ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.40% |
53INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.39% |
54SVRA | SAVARA INC | Healthcare | $1.13B | 0.35% |
55CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.35% |
56NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.34% |
57WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.34% |
58JBIO | JADE BIOSCIENCES INC | Healthcare | $1.03B | 0.32% |
59AVTX | AVALO THERAPEUTICS INC | Healthcare | $1.02B | 0.31% |
60BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.31% |
61OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 0.31% |
62FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.31% |
63ANRO | ALTO NEUROSCIENCE INC | Healthcare | $967M | 0.30% |
64ANNX | ANNEXON INC | Healthcare | $950M | 0.29% |
65PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.27% |
66ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.24% |
67DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.24% |
68RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.23% |
69CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 0.23% |
70CLYM | CLIMB BIO INC | Healthcare | $727M | 0.22% |
71OMER | OMEROS CORP | Healthcare | $701M | 0.22% |
72TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.20% |
73ACHV | ACHIEVE LIFE SCIENCES INC | Healthcare | $644M | 0.20% |
74STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.18% |
75IMMX | IMMIX BIOPHARMA INC | Healthcare | $558M | 0.17% |
76RLMD | RELMADA THERAPEUTICS INC | Healthcare | $550M | 0.17% |
77CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.16% |
78ZURA | ZURA BIO LTD | Healthcare | $518M | 0.16% |
79KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.14% |
80PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.13% |
81TENX | TENAX THERAPEUTICS INC | Healthcare | $420M | 0.13% |
82ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.12% |
83EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.12% |
84CV | CAPSOVISION INC | Healthcare | $335M | 0.10% |
85VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.10% |
86LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.10% |
87SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.08% |
88SRZN | SURROZEN INC | Healthcare | $255M | 0.08% |
89GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.07% |
90KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.07% |
91FOCL | FOCAL INC | Healthcare | $204M | 0.06% |
92OWLT | OWLET INC | Healthcare | $162M | 0.05% |
93VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.04% |
94SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.04% |
95LONA | LEONABIO INC | Healthcare | $68M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $325.68B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 82% toward Large, 66% toward Growth. +10% unclassified (8 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 19%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 33.8% | -30.5% |
| 3 yearsp.a. | 24.6% | 8.6% |
| 5 yearsp.a. | 6.2% | -1.9% |
| 10 yearsp.a. | 10.9% | -2.3% |
| Since inceptionp.a. | 9.2% | -4.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 12.9% | -4.9% |
| 2025 | 31.7% | -6.6% |
| 2024 | 29.4% | 31.4% |
| 2023 | -6.1% | -21.3% |
| 2022 | -12.7% | 12.3% |
| 2021 | 1.7% | 0.0% |
| 2020 | 33.6% | -27.6% |
| 2019 | 23.4% | 16.9% |
| 2018 | -4.5% | -4.5% |
| 2017 | 19.5% | -0.6% |
| 2016 | -20.1% | -10.6% |
| 2015 | 1.8% | -11.4% |
| 2014 | 18.4% | -25.1% |
| 2013 | 58.5% | 10.8% |
| 2012 | 20.7% | -10.4% |
| 2011 | 13.6% | 2.4% |
| 2010 | 18.5% | 1.7% |
| 2009 | 26.1% | -5.8% |
| 2008 | -24.1% | -0.5% |
| 2007 | 0.9% | -7.8% |
| 2006 | -0.6% | -13.3% |
| 2005 | 4.6% | 19.0% |
| 2004 | 21.7% | 21.2% |
| 2003 | 25.6% | -24.4% |
| 2002 | -18.8% | 34.1% |
| 2001 | 1.7% | 7.9% |
| 2000 | -7.9% | -67.2% |
| 1999 | 29.6% | 39.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare IntMom Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a IntMom signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.